000053914 001__ 53914
000053914 005__ 20200621144035.0
000053914 0247_ $$2pmid$$apmid:17127177
000053914 0247_ $$2DOI$$a10.1016/j.nucmedbio.2006.09.004
000053914 0247_ $$2WOS$$aWOS:000242840500012
000053914 0247_ $$2ISSN$$a1872-9414
000053914 0247_ $$2altmetric$$aaltmetric:3411457
000053914 037__ $$aPreJuSER-53914
000053914 041__ $$aeng
000053914 082__ $$a610
000053914 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000053914 1001_ $$0P:(DE-Juel1)VDB64651$$aSalber, D.$$b0$$uFZJ
000053914 245__ $$aDifferential uptake of [(18)F]FET and [(3)H]l-methionine in focal cortical ischemia
000053914 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2006
000053914 300__ $$a1029 - 1035
000053914 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000053914 3367_ $$2DataCite$$aOutput Types/Journal article
000053914 3367_ $$00$$2EndNote$$aJournal Article
000053914 3367_ $$2BibTeX$$aARTICLE
000053914 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000053914 3367_ $$2DRIVER$$aarticle
000053914 440_0 $$04644$$aNuclear Medicine and Biology$$v33$$x0883-2897$$y8
000053914 500__ $$aRecord converted from VDB: 12.11.2012
000053914 520__ $$aAmino acids such as [(11)C-methyl]l-methionine are particularly useful in brain tumor diagnosis, but unspecific uptake (e.g., in cerebral ischemia) has been reported. O-(2-[(18)F]fluoroethyl)-l-tyrosine ([(18)F]FET) shows a clinical potential similar to that of l-methionine (MET) in brain tumor diagnosis but is applicable on a wider clinical scale. The aim of this study was to evaluate the uptake of [(18)F]FET and [(3)H]MET in focal cortical ischemia in rats by dual-tracer autoradiography.Focal cortical ischemia was induced in 25 CDF rats using the photothrombosis (PT) model. At different time points up to 6 weeks after the induction of PT, [(18)F]FET and [(3)H]MET were injected intravenously. Additionally, contrast-enhanced magnetic resonance imaging (MRI) was performed in 10 animals. One hour after tracer injection, brains were cut in coronal sections and evaluated by dual-tracer autoradiography. Lesion-to-brain (L/B) ratios were calculated by dividing the maximal uptake in the lesion by the mean uptake in the brain. An L/B ratio of >2.0 was considered indicative of pathological uptake. Histological slices were stained by cresyl violet and supplemented by immunostainings for glial fibrillary acidic protein (GFAP) and CD68 in selected cases.A variably increased uptake of both tracers was observed in the PT lesion and its demarcation zone up to 7 days after PT for [(18)F]FET and up to 6 weeks for [(3)H]MET. The cutoff level of 2.0 was exceeded in 12/25 animals for [(18)F]FET and in 18/25 animals for [(3)H]MET. Focally increased tracer uptake matched contrast enhancement in MRI in 3/10 cases for [(18)F]FET and in 5/10 cases for [(3)H]MET. Immunohistochemical staining in lesions with differential uptake of [(18)F]FET and [(3)H]MET revealed that selective uptake of [(18)F]FET was associated with GFAP-positive astrogliosis while selective [(3)H]MET uptake correlated with CD68-positive macrophage infiltration.[(18)F]FET, like [(3)H]MET, may exhibit significant uptake in the periphery of cortical infarctions, which has to be considered in the differential diagnosis of unknown brain lesions. There are discrepancies between [(18)F]FET and [(3)H]MET uptake in the area of infarctions that appear to be caused by the preferential uptake of [(18)F]FET in reactive astrocytes versus the preferential uptake of [(3)H]MET in macrophages.
000053914 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000053914 588__ $$aDataset connected to Web of Science, Pubmed
000053914 65320 $$2Author$$acortical ischemia
000053914 65320 $$2Author$$aphotothrombosis
000053914 65320 $$2Author$$aO-(2-[F-18]fluoroethyl)-L-tyrosine
000053914 65320 $$2Author$$a[H-3]L-methionine
000053914 65320 $$2Author$$aautoradiography
000053914 650_2 $$2MeSH$$aAnimals
000053914 650_2 $$2MeSH$$aBrain Ischemia: metabolism
000053914 650_2 $$2MeSH$$aCerebral Cortex: blood supply
000053914 650_2 $$2MeSH$$aFluorine Radioisotopes: diagnostic use
000053914 650_2 $$2MeSH$$aMale
000053914 650_2 $$2MeSH$$aMethionine: pharmacokinetics
000053914 650_2 $$2MeSH$$aRadiopharmaceuticals: pharmacokinetics
000053914 650_2 $$2MeSH$$aRats
000053914 650_2 $$2MeSH$$aRats, Inbred F344
000053914 650_2 $$2MeSH$$aTritium: diagnostic use
000053914 650_2 $$2MeSH$$aTyrosine: analogs & derivatives
000053914 650_2 $$2MeSH$$aTyrosine: pharmacokinetics
000053914 650_7 $$00$$2NLM Chemicals$$aFluorine Radioisotopes
000053914 650_7 $$00$$2NLM Chemicals$$aO-(2-fluoroethyl)tyrosine
000053914 650_7 $$00$$2NLM Chemicals$$aRadiopharmaceuticals
000053914 650_7 $$010028-17-8$$2NLM Chemicals$$aTritium
000053914 650_7 $$055520-40-6$$2NLM Chemicals$$aTyrosine
000053914 650_7 $$063-68-3$$2NLM Chemicals$$aMethionine
000053914 650_7 $$2WoSType$$aJ
000053914 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b1$$uFZJ
000053914 7001_ $$0P:(DE-HGF)0$$aPauleit, D.$$b2
000053914 7001_ $$0P:(DE-HGF)0$$aReifenberger, G.$$b3
000053914 7001_ $$0P:(DE-HGF)0$$aSabel, M.$$b4
000053914 7001_ $$0P:(DE-Juel1)131794$$aShah, J. N.$$b5$$uFZJ
000053914 7001_ $$0P:(DE-Juel1)VDB551$$aHamacher, K.$$b6$$uFZJ
000053914 7001_ $$0P:(DE-Juel1)131816$$aCoenen, H. H.$$b7$$uFZJ
000053914 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b8$$uFZJ
000053914 773__ $$0PERI:(DE-600)1498538-x$$a10.1016/j.nucmedbio.2006.09.004$$gVol. 33, p. 1029 - 1035$$p1029 - 1035$$q33<1029 - 1035$$tNuclear medicine and biology$$v33$$x1872-9614$$y2006
000053914 8567_ $$uhttp://dx.doi.org/10.1016/j.nucmedbio.2006.09.004
000053914 909CO $$ooai:juser.fz-juelich.de:53914$$pVDB
000053914 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000053914 9141_ $$y2006
000053914 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000053914 9201_ $$0I:(DE-Juel1)VDB54$$d31.12.2006$$gIME$$kIME$$lInstitut für Medizin$$x0
000053914 9201_ $$0I:(DE-Juel1)VDB53$$d31.12.2006$$gINC$$kINC$$lInstitut für Nuklearchemie$$x1
000053914 9201_ $$0I:(DE-82)080010_20140620$$gJARA$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x2
000053914 970__ $$aVDB:(DE-Juel1)84592
000053914 980__ $$aVDB
000053914 980__ $$aConvertedRecord
000053914 980__ $$ajournal
000053914 980__ $$aI:(DE-Juel1)INB-3-20090406
000053914 980__ $$aI:(DE-Juel1)INM-5-20090406
000053914 980__ $$aI:(DE-82)080010_20140620
000053914 980__ $$aUNRESTRICTED
000053914 981__ $$aI:(DE-Juel1)INB-3-20090406
000053914 981__ $$aI:(DE-Juel1)INM-5-20090406
000053914 981__ $$aI:(DE-Juel1)VDB1046